Acute Lymphoblastic Leukemia Market is Expected to Grow with 4.8% CAGR During the Study Period of 2017-30 in 7 Major Markets

Acute Lymphoblastic Leukemia Market is Expected to Grow with 4.8% CAGR During the Study Period of 2017-30 in 7 Major Markets

PR Newswire

LAS VEGAS, June 25, 2020

"Growth of ALL market is expected to be driven by rising incident cases of ALL, steady uptake of approved and emerging therapies along with an expected increase in investment in the R&D activities. CAR-T cell therapies are expected to dominate the Acute lymphoblastic leukemia market as five of the immunotherapies in the pipeline are geared up to enter the market by 2023."

LAS VEGAS, June 25, 2020 /PRNewswire/ -- DelveInsight has announced the expansion of the forecast period to 2020-2030 for its report on 'Acute Lymphoblastic Leukemia (ALL) Market Insight, Epidemiology and Market Forecast -2030'.


Report Findings

Request for Free Sample Pages of the Report:

Acute lymphocytic leukemia (ALL), also known as acute lymphoblastic leukemia, is a type of cancer that affects the blood and bone marrow. The tumor begins from young white blood cells known as lymphocytes in the bone marrow; mainly characterized by the production of immature white blood cells, called lymphoblasts or leukemic blasts in excess. ALL is caused by a lack of normal circulating blood cells. The exact causes of acute lymphocytic leukemia remain mostly unknown; still, it is thought to result from mutations in one or more of the genes that usually control blood cell development. This mutation will result in abnormal growth. It is mainly classified into B-cell and T-cell ALL. ALL can occur at any age but is more common in young children (0–14 years), and it develops quickly, so people are usually only unwell for only a short period before they are diagnosed.

 Acute lymphocytic leukemia, an uncommon cancer of the blood, had a total incidence of 10,341 in the 7MM in 2017. The ALL incidence is expected to further rise during the forecast period 2020-2030. The US accounted for approximately 50% of the total Acute lymphocytic leukemia incident population in the 7MM. Among EU5 countries, Germany topped the list of highest ALL incident cases, with France following behind. Spain accounted for the least ALL incidence among all the 7MM countries.

The Acute lymphocytic leukemia epidemiological analysis demonstrated a higher male preponderance, and approximately 56% of the affected population belonged to the age group <20 years.

DelveInsight's Acute lymphocytic leukemia epidemiological segment of the report provides historical as well as forecasted trends for the period 2020-30 bifurcating the patient pool into

Acute lymphocytic leukemia Market

The Acute lymphocytic leukemia treatment options include Chemotherapy, Post Remission Therapy (Consolidation and Maintenance Therapy), Targeted Therapy, Immunotherapy, and CAR-T cell therapy. Stem Cell Transplant is also an alternative for the patients who are at early stages of treatment with high-risk subtypes of ALL.

However, Immunotherapy offers a broad and promising approach to cure cancer using the body's immune system. After the first-ever FDA approval to CAR-T cell therapy Kymriah (Tisangenlecleucel; Novartis) for the treatment of ALL, several advances in the clinical setting have been made, leading to more effective treatment strategies. As of 2020, Targeted immunotherapy drugs are available to address the relapsed or refractory Acute lymphocytic leukemia cases and are a favorable option for the treatment of older patients within clinical practice. However, there is a significant requirement to develop appropriate strategies for adolescents and young adult ALL patients, which fall between the standard categories of paediatric or adult ALL.

Acute lymphocytic leukemia Marketed Therapies

Present Acute lymphocytic leukemia market scenario is enriched with several companies evaluating novel drug molecules and targets as well as finding ways to add to the efficacy of existing ALL treatment approaches. DelveInsight estimates that Blincyto with its broader indication approval shall be at an early mover advantage to other lines of settings and is expected to dominate the second-line setting as well. However, it would be met by stiff competition from Besponsa and Kymriah.

The Acute lymphocytic leukemia pipeline hosts CAR-T cell therapies including KTE-X19 (Gilead Sciences), AUTO1 (Autolus Limited), PBCAR0191 (Precision BioSciences/Servier), UCART19 (Servier/Allogene), and Lisocabtagene Maraleucel/JCAR017 (Bristol-Myers Squibb), which are the major factors providing momentum to the Acute lymphocytic leukemia market.

Acute lymphocytic leukemia Pipeline Therapies

The dynamics of the overall Acute lymphocytic leukemia market is anticipated to shift positively during the forecast period 2020-30 attributable to rising ALL incidence, improvement in the rise in the number of healthcare spending across the world, a shifted focus to targeted immunotherapies and heightened interest of the major pharma and biotech players. However, there exist barriers that are expected to slow down the growth of ALL market as well. Due to the fact that it is uncommon cancer, there is difficulty in the recruitment of patients into clinical trials. Moreover, the cost of immunotherapies has always been questioned as most of the times, they are unaffordable. The entry of generics such as Sprycel (dasatinib) is another speed-breaker reducing the speed of the growth of the Acute lymphocytic leukemia market.

Identify Key Trends of Acute lymphocytic leukemia Market:

Scope of the Report

Reason to purchase

Table of Contents


Key Insights


Executive Summary of Acute lymphocytic leukemia


SWOT Analysis of Acute lymphocytic leukemia


Acute lymphocytic leukemia Market Overview at a Glance


Acute lymphocytic leukemia: Disease Background and Overview


Acute lymphocytic leukemia Diagnosis


Acute lymphocytic leukemia Epidemiology and Patient Population


The United States Acute lymphocytic leukemia Epidemiology


EU-5 Country-wise Acute lymphocytic leukemia Epidemiology


Japan Acute lymphocytic leukemia Epidemiology


Current Acute lymphocytic leukemia Treatment Practices


Acute lymphocytic leukemia Treatment Algorithms


Acute lymphocytic leukemia Guideline


Unmet Needs in Acute lymphocytic leukemia Market


Acute lymphocytic leukemia: Patient Journey


Key Endpoints in Acute lymphocytic leukemia Clinical Trials


Acute lymphocytic leukemia Marketed Therapies


Emerging Acute lymphocytic leukemia Therapies


Conjoint Analysis of Acute lymphocytic leukemia


Acute lymphocytic leukemia: Seven Major Market Analysis


7MM Acute lymphocytic leukemia Market Size


United States Acute lymphocytic leukemia Market Size


EU-5 Acute lymphocytic leukemia Market Size


Japan Acute lymphocytic leukemia Market Size


Market Access and Reimbursement of Acute lymphocytic leukemia Therapies


Acute lymphocytic leukemia Market Drivers


Acute lymphocytic leukemia Market Barriers




DelveInsight Capabilities




About DelveInsight

Request a WebEx Walkthrough of the Report:

Related Reports

Acute Lymphoblastic Leukemia (ALL) - Pipeline Insights, 2020
"Acute Lymphoblastic Leukemia Pipeline " report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Acute Lymphoblastic Leukemia market. A detailed picture of the Acute Lymphoblastic Leukemia (ALL) pipeline landscape is provided, which includes the disease overview and Acute Lymphoblastic Leukemia (ALL) treatment guidelines.

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL)- Market Insights and Market Forecast- 2030
DelveInsight's "CAR T-Cell Therapy for Acute Lymphoblastic Leukemia " report delivers an in-depth understanding of the CAR T-Cell Therapy use for Acute Lymphoblastic Leukemia as well as the CAR T-Cell Therapy market trends for Acute Lymphoblastic Leukemia in the 6MM, i.e., United States and EU5 (Germany, Spain, Italy, France and the United Kingdom).

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact us:

Shruti Thakur


Voltar noticias em Inglês